Healthy Future, Teva’s sustainability strategy, guides how we care for people, the planet and our business—because they are all connected. Addressing global challenges and supporting our communities, while ensuring our business success, allows us to continue providing medicines to the millions of patients around the world who count on us.
We hold ourselves accountable.
Meeting or exceeding bold targets and setting the bar higher with new ones |
largest issuer of sustainability-linked bonds in the pharma sector and second largest in the world (total issuance: $7.5B), connecting sustainability commitments and progress to our business strategy |
530M |
= 10M doses
8 |
$40.9B |
49% |
43% of Teva’s electricity comes from renewable sources, targeting 100% by 2035 |
|
27% reduction in scope 1 and 2 greenhouse gas (GHG) emissions (vs. 2019), exceeding our 2025 target two years ahead of schedule |
12% reduction in scope 3 GHG emissions (vs. 2020), tracking strongly against our 2030 target |
|
Aim to achieve net zero emissions by 2045 |
94% |
~100% |
60% |
Top 3% |
1 of first 2 companies to receive the product-level British Standards Institution (BSI) certification for responsible manufacturing practices that minimize antimicrobial resistance risk |
|
Active member of the Pharmaceutical Supply Chain Initiative (PSCI), a coalition of pharmaceutical and healthcare companies that share a vision of better social, environmental and economic outcomes |
A- Climate score and B Water score from CDP, a non-profit that helps companies disclose environmental impact | |
GHG emissions near-term reduction targets (scope 1, 2 and 3) validated by Science Based Targets initiative (SBTi) |
|
Global Environment, Health and Safety Management System aligned with international standards, including ISO 14001, 45001 and EMAS |
Our progress is being recognized. |
Improved score in 4 key ESG ratings
(vs. 2022) MSCI, Sustainalytics, ISS, EcoVadis
Best Healthcare Company for Sustainability Reporting
from ESG Investing Awards
Corporate Social Responsibility Initiative of the Year
from Global Generics and Biosimilars Awards